18.78EUR+0.97%Mkt Cap: —P/E: —1d ago
Formycon AG, a biotechnology company, develops biosimilar drugs in Germany and Switzerland. It provides ranibizumab and aflibercept used in the treatment of neovascular age-related macular degeneration, diabetic macular …
Industry Peers
Healthcare$1.14TUSDP/E 43.0
$658.89BUSDP/E 31.7
$462.68BUSDP/E 74.0
$375.50BUSDP/E 122.7
$341.92BUSDP/E 24.5
$348.81BUSDP/E 25.0
$279.13BUSDP/E 22.3
$274.07BUSDP/E 23.6
$240.45BUSDP/E 24.5
$231.49BUSDP/E 24.5
$238.75BUSDP/E 27.4
$226.85BUSDP/E 33.1
$190.75BUSDP/E 11.3
$198.81BUSDP/E 36.9
$183.02BUSD
$160.96BUSDP/E 37.2
$151.78BUSDP/E 38.6
$142.49BUSDP/E 45.6
$139.84BUSDP/E 32.2
$138.11BUSDP/E 14.9
Key Statistics
Company
Market Cap—
Enterprise Value304.51M $
Revenue (TTM)66.57M $
Gross Profit15.19M $
Net Income (TTM)-27.32M $
Revenue/Share3.767 USD
Last Price18.78 EUR
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees196
CountryGB
SectorHealthcare
Industry—
ISINDE000A1EWVY8
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA29.78
EV/Revenue4.57
P/S—
P/B0.84
EPS (TTM)-1.22
EPS (Forward)—
52W Range
18.3096% of range18.80
52W High18.80 EUR
52W Low18.30 EUR
Profitability
Gross Margin22.81%
Oper. Margin-65.87%
EBITDA Margin15.36%
Profit Margin-41.04%
ROE-6.33%
ROA-1.27%
Growth
Revenue Growth242.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-1.32M $
CapEx (TTM)—
FCF Margin-49.34%
FCF Yield—
Net Debt-47.03M $
Net Debt/EBITDA-4.60
Balance Sheet
Debt/Equity2.21
Current Ratio2.04
Quick Ratio1.42
Book Value/Sh21.82 EUR
Cash/Share2.930 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.9.34M
Float—
Insiders30.00%
Institutions31.26%
Technical
SMA 5050.84 (-63.1%)
SMA 20058.79 (-68.1%)
Beta0.72
S&P 52W Chg20.80%
Avg Vol (30d)95
Avg Vol (10d)1.31K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—